—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Argen-X (ARGX.BR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ARGX.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ARGX.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Argen-X

ARGX.BR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Argen-X develops antibody therapies for autoimmune disease, selling VYVGART and VYVGART HYTRULO for conditions such as myasthenia gravis and CIDP. Its pipeline extends the same FcRn-blocking approach into other immune disorders and adds candidates aimed at inflammation and antibody-driven disease. It works with partners including Zai Lab, Halozyme and AbbVie to develop or commercialise specific molecules. The company is based in Amsterdam and listed in Brussels.
Where it sits in the stack
Argen-X carries no seat in Rubin, our AI build-out index, and sits instead in the Healthcare sector of the wider Closelooknet universe, where it is grouped with other scored biopharma names rather than tied to any hardware or software layer.
Who it is priced against
Closelooknet's peer group places it with other scored healthcare names — Eli Lilly, Regeneron, BeiGene, UCB and Medpace among them — reflecting shared sector rather than shared disease area; the market also names Argenx's ADR line as the same company traded in New York.
Why Closelooknet tracks it
It carries a Closelooknet score with momentum as the strongest module and valuation as the weakest; it holds no seat in Rubin or our other indices and has not drawn quotes in the diary's editions.
What the diary watches
Whether commercial uptake of VYVGART across its approved uses keeps momentum ahead of a valuation module that the score already marks as the weak point.

Argen-X (ARGX.BR) trades on the BR exchange in Belgium.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Argen-X (ARGX.BR)?

Argen-X trades as ARGX.BR on the BR exchange (Belgium) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ARGX.BR in a Closelooknet index?

Not currently — Argen-X is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does ARGX.BR trade against its moving averages?

Pullback inside an uptrend stack: Trades +0% vs the 50-day and +13.2% vs the 200-day average, 9.8% below the 52-week high and +46.9% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Argen-X compare with its peers?

Against its peer group (Biotechnology), Argen-X (ARGX.BR) sits 9.8% below its 52-week high, 0.0% above its 50-day average; BB Biotech AG (BION.SW) is 12.9% below, BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below. Put any of them next to ARGX.BR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Argen-X do?

Argen-X develops antibody therapies for autoimmune disease, selling VYVGART and VYVGART HYTRULO for conditions such as myasthenia gravis and CIDP. Its pipeline extends the same FcRn-blocking approach into other immune disorders and adds candidates aimed at inflammation and antibody-driven disease. It works with partners including Zai Lab, Halozyme and AbbVie to develop or commercialise specific molecules. Closelooknet's peer group places it with other scored healthcare names — Eli Lilly, Regeneron, BeiGene, UCB and Medpace among them — reflecting shared sector rather than shared disease area; the market also names Argenx's ADR line as the same company traded in New York.

Where does Argen-X sit in the AI build-out?

Argen-X carries no seat in Rubin, our AI build-out index, and sits instead in the Healthcare sector of the wider Closelooknet universe, where it is grouped with other scored biopharma names rather than tied to any hardware or software layer. It carries a Closelooknet score with momentum as the strongest module and valuation as the weakest; it holds no seat in Rubin or our other indices and has not drawn quotes in the diary's editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARGX.BR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.